EQL Pharma Q2 operating profit rises year on year to SEK 22.4 million; Q2 sales climb 82% to SEK 157.2 million

• EQL Pharma’s operating profit rose year over year to SEK 22.4 million in the second quarter of fiscal 2026/27.
• Sales jumped 82% year over year to SEK 157.2 million, helped by competitors’ shortages of a key product.
• Write-downs of receivables and inventory totaled SEK 15 million, while leverage stood at 6.6 times EBITDA, above target.
• Marketing authorizations were secured for the first three Special Generics products with significant potential.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EQL Pharma AB published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.